Ann: Update to Interim Phase III Results for PI-88, page-11

Would have been nice to have some raw numbers quoted rather than definitive conclusions stating primary end point not met. Very high level of statistical significance required according to this ANN. It may be that there is separation between the 2 groups, but there is, for example, still 3% chance (i.e. P = 0.03) that this is due to chance so they had to accept and report that there is no difference. But with 40% more patients, this may well become statistically significant (within their pre-determined targets) and so become a positive result. Just can't tell at this stage!!! There may be absolutely no divergence of progression free survival curves whatsoever so it wouldn't matter if another 100000 patients were studied! impossible to tell at this stage unfortunately. The lack of dose-dependent effect in their PII is ringing alarm bells for me - so have sold at a loss, but will continue to watch as more data is released.